Bayer Stock Holds Above Key Moving Average as Court Dates and a Biotech Takeover Loom
20.06.2026 - 17:41:29 | boerse-global.de
The shares of Bayer have crept back above a technical threshold that traders are watching closely. At the close on Friday, the stock settled at €37.81, narrowly clearing the 50-day moving average, after a 4.85% gain over the week. Yet the real test for the German pharmaceutical and agriculture group is not chart-driven — it comes from a pair of landmark US court hearings and a newly closed deal in eye-care.
A $300M Bet on Eye Disease
Bayer confirmed it has wrapped up the acquisition of Perfuse Therapeutics, a private biotech focused on retinal diseases. The upfront payment is roughly $300 million, but the total deal value can climb to $2.45 billion if all development and sales milestones are met. The centrepiece is PER-001, an intravitreal implant designed to treat glaucoma and diabetic retinopathy. The drug candidate is currently in Phase II trials and was built on Perfuse’s proprietary sustained-release platform. Bayer is folding it into its ophthalmology portfolio, a move that CEO Bill Anderson sees as strengthening the pharma pipeline.
But that pipeline also faces headwinds. Bayer’s prostate-cancer drug Nubeqa is locked in a legal fight with Johnson & Johnson. In February, Bayer sued J&J, alleging that J&J’s rival drug Erleada is being marketed with a flawed real-world analysis that wrongly claims superiority. A federal judge in Manhattan refused to block those statements — a setback for Bayer. Then, on June 15, Bayer filed an amended complaint seeking a permanent injunction and damages. The stakes are high: Nubeqa booked €1.92 billion in sales over the first nine months of 2025, while Erleada generated €2.62 billion.
Supreme Court and a Settlement Hearing Dominate the Calendar
The bigger legal overhang for Bayer remains glyphosate. The US Supreme Court is set to weigh a fundamental question: whether federal warning labels on Roundup should pre-empt state-level duties to warn. The outcome will shape the direction of future lawsuits. Separately, a US judge has sent a proposed multibillion-dollar settlement back to a court in Missouri. The original settlement was valued at $7.25 billion. A critical hearing is scheduled for July 9.
Should investors sell immediately? Or is it worth buying Bayer?
With both events imminent, the stock is primed for volatility. A favourable Supreme Court ruling could reinforce the recent breakout above the 50-day line. Should the shares slip back below €37.80, a rapid pullback is on the cards.
Cash Flow Pressures and Analyst Divergence
The legal efforts come at a cost. For 2026 alone, Bayer expects roughly €5 billion in cash outflows tied to ongoing litigation. Free cash flow could turn as negative as €2.5 billion, and net financial debt may swell to €33 billion by year-end. Management is counting on stronger revenue from the agricultural and consumer health segments to help offset the drain.
Against that backdrop, analysts are split. UBS has a price target of €52, with analyst Matthew Weston highlighting the potential in both the pharma and crop-science divisions. Jefferies is more cautious, setting a target of €40.
Bayer at a turning point? This analysis reveals what investors need to know now.
Technically, the stock has risen more than 50% from its 52-week low of €25.09, but remains about 24% below its 52-week high of €49.93. The weekly advance of 4.85% has pushed it above the 200-day moving average as of June 17, but the real catalysts — and the real risks — lie in the courtroom.
Ad
Bayer Stock: New Analysis - 20 June
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
